The US Food and Drug Administration is changing the way it approves Covid-19 vaccines for Americans, a move that may limit ...

In the NEJM article, the FDA notes that covid booster uptake has been low in the US, with less than a quarter of people ...

The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The VRBPAC meeting comes the week after the World Health Organization (WHO) recommended that members consider using ...

"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

Novavax's shot is now fully approved in the U.S. Since 2022, the vaccine has been used under an emergency use authorization.

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

COVID-19 shots for healthy younger adults and children will no longer be routinely approved under a major new policy shift ...

The U.S. Food and Drug Administration (FDA ) leaders said on Tuesday they would adopt a new COVID-19 vaccination regulatory ...

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.